REJUVENATE BIO INC — Department of Defense SBIR Phase II: SOCOM182-002
REJUVENATE BIO INC — SBIR Phase II award from Department of Defense.
- Amount
- $1,445,046
- Agency
- Department of Defense · Special Operations Command
- Program / Phase
- SBIR · Phase II
- Topic
- SOCOM182-002
- Solicitation
- 18.2
- NAICS
- —
- Place of performance
- CA
- Period
- 2019-12-11 → 2022-05-10
Description
Special OperationsForces (SOF)are an integral aspect of the US military. SOF operators are among the most elite and highly qualified individuals in the U.S.military. As such, extraordinary physical and mental demands are placed upon them to excel in extreme environments for extended periods of time. This unrelenting cycle of combat deployments and intense pre-deployment training shortens the functional life of operators, a highly undesirable outcome. Rejuvenate Bio developed a gene therapy platform that identified genes that can increase the stress-resistance, health-span, and lifespan.We believe that these novel gene therapies will also enhance cognitive performance due to the neurotropic and brain specific genes being modulated. As a first step toward developing therapies for humans, we propose to measure the effect of these gene therapies on learning, memory, and focus.